Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus CARMOL HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus CARMOL HC.
ARAZLO vs CARMOL HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Carmol HC is a combination of urea (a keratolytic) and hydrocortisone (a corticosteroid). Urea softens and dissolves the intercellular matrix of the stratum corneum, promoting desquamation and enhancing penetration of hydrocortisone. Hydrocortisone suppresses inflammation by induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Apply a thin film to affected area twice daily; topical, not for ophthalmic or oral use.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
1-2 hours (hydrocortisone acetate); clinical effects persist longer due to local anti-inflammatory action; tissue half-life not well defined.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily renal excretion of metabolites (40-60%) as glucuronide and sulfate conjugates; <10% unchanged; biliary/fecal elimination accounts for <20%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid